Ask AI
ProCE Banner Activity

KOMET-007: Long-term Results From the Phase I Trial of Ziftomenib Plus 7 + 3 Intensive Induction Therapy in Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML

Slideset

Results from the cohort of patients with newly diagnosed NPM1-mutated or KMT2A-rearranged AML in the phase I KOMET-007 study demonstrated clinical activity with deep and durable responses with the combination of ziftomenib and intensive 7 + 3 chemotherapy across both molecular subtypes as well as a manageable safety profile.

Released: July 06, 2026

Share

Provided by

ProCE Banner

Supporters

This activity is supported by educational grants from Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation

Target Audience

This activity is intended for hematologists, oncologists, and other healthcare professionals who care for patients with hematologic malignancies.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate cutting-edge data from studies of hematologic malignancies at ASCO 2026 and EHA 2026 along with expert guidance to optimize personalized care and improve patient outcomes

  • Utilize prognostic and predictive biomarkers to accurately identify patients with hematologic malignancies most likely to benefit from specific targeted therapies and treatment strategies

  • Interpret newly released clinical data on novel agents, updated guidelines, and emerging therapeutic approaches for hematologic malignancies to accelerate their effective incorporation into clinical practice

  • Support informed shared decision-making for patients with hematologic malignancies through accessible discussion of the potential clinical implications of recently presented data at ASCO 2026 and EHA 2026